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Abstract
Background: Little evidence supports anticoagulant therapy as effective adjuvant therapy to reduce mortality overall in
sepsis. However, several studies suggest that anticoagulant therapy may reduce mortality in specific patients. This study
aimed to identify a subset of patients with high benefit profiles for anticoagulant therapy against sepsis.
Methods: This post hoc subgroup analysis of a nationwide multicentre retrospective registry was conducted in 42
intensive care units in Japan. Consecutive adult patients with sepsis were included. Treatment effects of anticoagulants,
e.g. antithrombin, recombinant thrombomodulin, heparin, and protease inhibitors, were evaluated by stratifying patients
according to disseminated intravascular coagulation (DIC) and Sequential Organ Failure Assessment (SOFA) score.
Intervention effects of anticoagulant therapy on in-hospital mortality and bleeding complications were analysed using
Cox regression analysis stratified by propensity scores.
Results: Participants comprised 2663 consecutive patients with sepsis; 1247 patients received anticoagulants and 1416
received none. After adjustment for imbalances, anticoagulant administration was significantly associated with reduced
mortality only in subsets of patients diagnosed with DIC, whereas similar mortality rates were observed in non-DIC
subsets with anticoagulant therapy. Favourable associations between anticoagulant therapy and mortality were observed
only in the high-risk subset (SOFA score 13–17; adjusted hazard ratio 0.601; 95 % confidence interval 0.451, 0.800) but not
in the subsets of patients with sepsis with low to moderate risk. Although the differences were not statistically significant,
there was a consistent tendency towards an increase in bleeding-related transfusions in all SOFA score subsets.
Conclusions: The analysis of this large database indicates anticoagulant therapy may be associated with a survival benefit
in patients with sepsis-induced coagulopathy and/or very severe disease.
Trial registration: University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR ID: UMIN000012543).
Registered on 10 December 2013.
Keywords: Anticoagulants, Sepsis, Retrospective studies, Subgroup analysis, Disseminated intravascular coagulation, DIC
* Correspondence: k.yamakawa0911@gmail.com
1Department of Emergency and Critical Care, Osaka General Medical Center,
3-1-56 Bandai-Higashi, Sumiyoshi-ku, Osaka 558-8558, Japan
2Department of Traumatology and Acute Critical Medicine, Osaka University
Graduate School of Medicine, 2-15 Yamadaoka, Suita, Osaka 565-0871, Japan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Yamakawa et al. Critical Care  (2016) 20:229 
DOI 10.1186/s13054-016-1415-1
Background
Sepsis invariably leads to haemostatic abnormalities
through the activation of inflammatory mediators and
vascular endothelial cell injury, which play a critical role
in inducing multiple organ dysfunction syndrome and
subsequent death [1–4]. Thus, anticoagulant therapies are
expected to be beneficial in the treatment of sepsis [5, 6].
Several anticoagulant therapies, such as recombinant
human activated protein C, antithrombin, recombinant
tissue factor pathway inhibitor, and recombinant human
soluble thrombomodulin (rhTM), have already been evalu-
ated as adjuvant therapy against sepsis [7–13]. However,
the efficacy of anticoagulant therapies in sepsis remains
a matter of dispute because of limited evidence that it
improves clinical outcomes.
Although most previous studies of anticoagulants did
not observe reduced mortality overall in patients with
sepsis, some subgroup analyses suggest that anticoagu-
lant therapies might be beneficial only in specific pa-
tients with sepsis. For example, the post hoc subgroup
analysis of a large multinational randomised controlled
trial (RCT) of antithrombin suggested that favourable
treatment effects of antithrombin were observed only in
patients with sepsis with predicted mortality between
30 % and 60 % according to the baseline Simplified
Acute Physiology Score II score [14]. Additionally, anti-
thrombin treatment was associated with a significant re-
duction in mortality only in patients suffering from
sepsis-induced disseminated intravascular coagulation
(DIC) and not in non-DIC patients [15]. We previously
demonstrated significant association between recombin-
ant human soluble thrombomodulin (rhTM) treatment
and favourable mortality outcome only in patients with
both sepsis-induced DIC and high risk of death accord-
ing to baseline Acute Physiology and Chronic Health
Evaluation (APACHE) II and Sequential Organ Failure
Assessment (SOFA) scores [16].
We thus hypothesised that anticoagulant therapies
might be effective only in patients with sepsis who
are at high risk of death and have DIC, and might not be
effective in other patients. This study aimed to analyse the
association between anticoagulant therapy and outcomes




This investigation was a post hoc subgroup analysis
of a multicentre nationwide retrospective cohort study
(the Japan Septic Disseminated Intravascular Coagulation
(J-Septic DIC) registry) conducted in 42 intensive care
units (ICUs) in Japan between January 2011 and December
2013 [17]. Patients were eligible for the registry if they had
a known or suspected infection on the basis of clinical data
and met the following criteria at the time of ICU admis-
sion: three or more signs of systemic inflammation and
sepsis-induced dysfunction of at least one organ or system,
and age ≥18 years. The exclusion criteria included the use
of warfarin/acetylsalicylic acid/thrombolytic therapy before
study entry; history of fulminant hepatitis, decompensated
liver cirrhosis, or other serious liver disorder; history of
haematologic malignant disease; other conditions increas-
ing the risk of bleeding; treatment with any chemotherapy
at study entry; and patients with missing data for primary
evaluation.
Participants were categorised into one of two groups:
the anticoagulant group, comprising patients who under-
went systemic administration at therapeutic doses of any
anticoagulant such as antithrombin, rhTM, heparin/hepar-
inoid or serine protease inhibitors, and the control group
comprising patients who received no anticoagulant ther-
apy. There was no predefined protocol on definite indica-
tions for anticoagulant therapy. Anticoagulant therapy in
patients with sepsis fulfilling the criteria for DIC was ap-
plied at the discretion of the attending physician based on
the treatment principles of each hospital. The standard
dosage and duration of treatment for each anticoagulant
agent used for sepsis-induced DIC in Japan are shown in
Additional file 1: Table S1. No patients were administered
recombinant human activated protein C because it had
not been approved for the treatment of sepsis in Japan.
Patients receiving prophylactic administration of low-dose
heparin/heparinoid for venous thromboembolism were in-
cluded in both groups.
This study followed the principles of the Declaration
of Helsinki and was approved by the institutional review
board of each participating hospital (Additional file 1:
Table S2). Because of the anonymous and retrospective
nature of this study, the board of each hospital waived the
need for informed consent. This study was registered with
the University Hospital Medical Information Network
Clinical Trial Registry (UMIN-CTR ID: UMIN000012543).
Data collection
A case report form was developed on which the following
information was recorded: age, sex, multiple illness sever-
ity scores on the day of ICU admission, source of ICU ad-
mission, pre-existing conditions, new organ dysfunction,
primary source of infection, and concomitant therapies
against sepsis. The severity of illness was evaluated at the
time of ICU admission according to the APACHE II score
and systemic inflammatory response syndrome score.
Organ dysfunction, defined as a SOFA sub-score ≥2 for
each organ, was assessed according to the SOFA score at
the time of ICU admission. DIC was diagnosed on the
basis of the criteria of the International Society on Throm-
bosis and Haemostasis (ISTH) and the Japanese Associ-
ation for Acute Medicine (JAAM) at the time of ICU
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admission. Details of the scoring systems for the ISTH
overt DIC [18, 19] and the JAAM DIC definitions [20] are
summarised in Additional file 1: Table S3.
The primary outcome measure was all-cause in-
hospital mortality. We also recorded as secondary
outcomes any bleeding complications, including the
occurrence of intracranial haemorrhage, transfusion
requirements related to bleeding, and bleeding requiring
surgical intervention.
Statistical analysis
The aim of this study was to identify a subset of patients
with high benefit profiles for anticoagulant therapy
against sepsis. Classification and regression trees for
survival data (survival CART) were thus used to classify
patients according to disease severity as determined by
SOFA and APACHE II scores and age.
Due to the retrospective nature of the study, there were
baseline imbalances between the two patient groups;
therefore, an adjusted mortality analysis was performed
using propensity scores [21, 22]. The propensity score for
receiving anticoagulant therapy was calculated using
multivariate logistic regression and included 32 independ-
ent variables comprising age, sex, disease severity, source
of ICU admission, past medical history of severe condi-
tions, new organ dysfunction, ICU characteristics, primary
source of infection, causal microorganisms, anticoagulant
therapy for indications other than DIC, and other thera-
peutic interventions (see Additional file 1: Table S4). The
c statistic was 0.818. The Hosmer-Lemeshow chi-square
value was 12.840 (df = 8), with a nonsignificant p value of
0.117, which indicates that the model fit well.
Patients were stratified into quintiles according to
their propensity scores. The overall association between
treatment and mortality outcomes was assessed using a
Cox regression model with strata defined by propensity
score hazard ratio (HR) and estimated 95 % confidence
interval (CI). For secondary outcomes of bleeding compli-
cations, the odds ratio (OR) and associated 95 % CI were
estimated by logistic regression stratified by propensity
score. Inverse probability-of-treatment weighting using the
propensity score was also used to assess the robustness of
the conclusions from the adjusted method, and no major
significant differences between the methods were found.
Descriptive statistics were calculated as medians
(interquartile range) or proportions, as appropriate.
Univariate differences between groups were assessed using
the Mann-Whitney U test, Kruskal-Wallis test, chi-square
test, or Fisher’s exact test. A p value <0.05 indicated statis-
tical significance. All statistical analyses were performed
with IBM SPSS Statistics version 22.0 for Windows
(SPSS Inc., Chicago, IL, USA), or R software package
version 3.2.0 (R Development Core Team).
Results
Study population and stratification by survival CART
The patient flow diagram is shown in Fig. 1. During the
study period, 3195 consecutive patients fulfilling the inclu-
sion criteria were registered in the J-Septic DIC registry
database. After excluding 532 patients who met at least one
exclusion criterion, we analysed 2663 patients as the final
study cohort. The anticoagulant group comprised 1247 pa-
tients and the control group comprised 1416 patients.
Survival CART analysis of SOFA scores revealed that
the first split point at which to partition mortality risk for
patients without anticoagulant therapy was a SOFA score
of 13, and the second split points were SOFA scores of 8
and 18 for all subsets of patients (Fig. 2). Therefore, the
associations between anticoagulant therapy and outcomes
were estimated in these four subsets. Patients were also
Fig. 1 Patient flow diagram. J-Septic DIC Japan Septic Disseminated Intravascular Coagulation, SCCM/ACCP Society of Critical Care Medicine/
American College of Chest Physicians, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation
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classified in the same manner according to APACHE II
score and age.
Baseline characteristics
Baseline characteristics and therapeutic interventions
of the overall study population are shown in Table 1.
Although patient characteristics such as age and sex were
similar between the anticoagulant and control groups,
illness severity, as indicated by SOFA, APACHE II, and
DIC scores, and the rate of new organ dysfunction showed
significant differences between groups. The most common
sites of underlying infection among all patients were the
abdomen (33 %) and the lung (25 %), but these rates were
not similar between treatment groups. The rate of con-
comitant therapeutic interventions against sepsis was also
different between groups.
Additionally, baseline characteristics and therapeutic
interventions in patients treated or not treated with anti-
coagulant in the specific subset according to baseline
DIC status and SOFA score are shown in Table 2 and
Additional file 1: Table S5, respectively. The anticoagulant
and control groups of the DIC-positive subset were well
balanced in age, sex, rate of new organ dysfunction, and
primary source of infection, whereas in the DIC-negative
subset, there were some differences between the two
groups. Baseline severity of the coagulation disorder deter-
mined by JAAM DIC scores and the rate of concomitant
therapeutic interventions were both significantly higher in
the anticoagulant group relative to the control group in
the two subsets with and without ISTH overt DIC.
Mortality according to baseline DIC status
Survival curves for the anticoagulant and control groups
in the prediction model are shown in Fig. 3, according
to covariates of propensity scores for subsets determined
by DIC status diagnosed using both the ISTH overt
DIC and JAAM DIC criteria. Significant associations
between anticoagulant therapy and lower in-hospital
mortality were observed only in the subsets of pa-
tients diagnosed with DIC (adjusted HR 0.609; 95 %
CI 0.456, 0.814; p = 0.001 for the subset positive for
ISTH overt DIC and adjusted HR 0.685; 95 % CI 0.559,
0.839; p <0.001 for the subset positive for JAAM DIC),
whereas similar mortality rates were observed in the
non-DIC subsets with anticoagulant therapy (adjusted
HR 0.941; 95 % CI 0.773, 1.145; p = 0.543 for the sub-
set negative for ISTH overt DIC and adjusted HR
1.104; 95 % CI 0.839, 1.453; p = 0.478 for the subset
negative for JAAM DIC).
Mortality according to baseline SOFA score
Survival curves for the anticoagulant and control groups
in the prediction model are shown in Fig. 4 according to
covariates of propensity scores for subsets determined
by baseline SOFA scores. Cox regression analysis sug-
gested that anticoagulant therapy was significantly asso-
ciated with reduced mortality but only in patients in the
high-risk subset (SOFA 13–17; adjusted HR 0.601; 95 %
CI 0.451, 0.800; p <0.001). In contrast, no association
with survival was evident in the low-risk subset (SOFA
≤7; adjusted HR 1.063; 95 % CI 0.716, 1.580; p = 0.761)
and moderate-risk subset (SOFA 8–12; adjusted HR
0.927; 95 % CI 0.728, 1.181; p = 0.540). The estimated
survival rates in the very high-risk subset were similar in
the treated and untreated groups (SOFA ≥18; adjusted
HR 0.915; 95 % CI 0.418, 2.003; p = 0.825), but this
analysis was not definitive because of the small sample
sizes of the subsets.
Fig. 2 Patient stratification according to baseline Sequential Organ Failure Assessment (SOFA) score using the classification and regression tree method
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Mortality according to other baseline characteristics
A similar tendency was observed in the analysis of sub-
sets based on a number of other clinical measures of
baseline illness severity (Fig. 5 and Additional file 1:
Table S6). When the population was separated into sub-
sets according to APACHE II scores, an insignificant









Age in years 73 (63–81) 72 (62–80) 73 (63–81) 0.034
Male sex 1576 (59 %) 716 (57 %) 860 (61 %) 0.089
Illness severity
SIRS score 3 (2–4) 3 (2–4) 3 (2–4) 0.508
SOFA score 9 (6–12) 10 (8–13) 8 (5–11) <0.001
APACHE II score 22 (16–28) 23 (18–29) 21 (16–27) <0.001
ISTH DIC score 3 (1–4) 4 (2–5) 2 (1–4) <0.001
JAAM DIC score 4 (2–6) 5 (3–6) 3 (2–5) <0.001
Source of ICU admission <0.001
Emergency department 1256 (47 %) 527 (42 %) 729 (52 %) -
Ward 711 (27 %) 366 (29 %) 345 (24 %) -
Other hospital 696 (26 %) 354 (28 %) 342 (24 %) -
Pre-existing condition
Liver insufficiency 19 (1 %) 12 (1 %) 7 (1 %) 0.171
Chronic heart failure 143 (5 %) 76 (6 %) 67 (5 %) 0.122
Chronic respiratory disorder 102 (4 %) 42 (3 %) 60 (4 %) 0.266
Chronic haemodialysis 209 (8 %) 84 (7 %) 125 (9 %) 0.051
Immunocompromised 280 (11 %) 130 (10 %) 150 (11 %) 0.899
New organ dysfunction (SOFA sub-scores ≥2)
Respiratory 1792 (88 %) 851 (68 %) 941 (67 %) 0.341
Cardiovascular 1761 (66 %) 934 (75 %) 827 (58 %) <0.001
Renal 1279 (48 %) 707 (57 %) 572 (40 %) <0.001
Hepatic 441 (17 %) 253 (20 %) 188 (13 %) <0.001
Coagulation 957 (36 %) 591 (47 %) 366 (26 %) <0.001
Primary source of infection <0.001
Abdomen 881 (33 %) 460 (37 %) 421 (30 %) -
Lung 677 (25 %) 269 (22 %) 408 (29 %) -
Urinary tract 456 (17 %) 221 (18 %) 235 (17 %) -
Bone/soft tissue 309 (12 %) 146 (12 %) 163 (12 %) -
Central nervous system 57 (2 %) 30 (2 %) 27 (2 %) -
Other/unknown 283 (11 %) 121 (10 %) 162 (11 %) -
Other therapeutic interventions
Immunoglobulin 800 (30 %) 590 (47 %) 210 (15 %) <0.001
Low-dose steroid 624 (23 %) 401 (32 %) 223 (16 %) <0.001
Renal replacement therapy 830 (31 %) 566 (45 %) 264 (19 %) <0.001
PMX-DHP 574 (22 %) 410 (33 %) 164 (12 %) <0.001
Surgical intervention 1153 (43 %) 617 (50 %) 536 (38 %) <0.001
Data are expressed as group medians (interquartile range) or proportion (%). SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure
Assessment, APACHE Acute Physiology and Chronic Health Evaluation, ISTH International Society on Thrombosis and Haemostasis, DIC disseminated intravascular
coagulation, JAAM Japanese Association for Acute Medicine, ICU intensive care unit, PMX-DHP polymyxin B direct haemoperfusion
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Table 2 Baseline characteristics of the patients with and without DIC diagnosed by ISTH overt DIC criteria treated or untreated with
anticoagulants











Age in years 72 (63–80) 73 (63–81) 0.127 72 (61–80) 73 (63–82) 0.314
Male sex 485 (60 %) 743 (61 %) 0.611 231 (53 %) 117 (61 %) 0.098
Illness severity
SIRS score 3 (2–4) 3 (2–4) 0.522 3 (3–4) 3 (3–4) 0.078
SOFA score 9 (7–12) 7 (5–10) <0.001 12 (9–14) 12 (9–15) 0.520
APACHE II score 23 (17–28) 20 (15–26) <0.001 25 (19–30) 24 (18–33) 0.342
ISTH DIC score 3 (2–4) 2 (1–3) <0.001 6 (5–6) 6 (5–6) 0.411
JAAM DIC score 4 (3–5) 2 (1–4) <0.001 7 (6–8) 6 (5–8) 0.004
Source of ICU admission <0.001 0.395
Emergency department 349 (43 %) 639 (52 %) - 178 (41 %) 90 (47 %) -
Ward 233 (29 %) 294 (24 %) - 133 (31 %) 51 (26 %) -
Other hospital 232 (29 %) 290 (24 %) - 122 (30 %) 52 (27 %) -
Pre-existing condition
Liver insufficiency 7 (0.9 %) 3 (0.2 %) 0.100 5 (1 %) 4 (2 %) 0.468
Chronic heart failure 49 (6 %) 60 (5 %) 0.315 27 (6 %) 7 (4 %) 0.251
Chronic respiratory disorder 31 (4 %) 50 (4 %) 0.817 11 (3 %) 10 (5 %) 0.097
Chronic haemodialysis 54 (7 %) 98 (8 %) 0.264 30 (7 %) 27 (14 %) 0.006
Immunocompromised 86 (11 %) 134 (11 %) 0.827 44 (10 %) 16 (8 %) 0.557
New organ dysfunction (SOFA sub-scores ≥2)
Respiratory 565 (69 %) 812 (66 %) 0.161 286 (66 %) 129 (67 %) 0.927
Cardiovascular 605 (74 %) 681 (56 %) <0.001 329 (76 %) 146 (76 %) 0.920
Renal 416 (51 %) 454 (37 %) <0.001 291 (67 %) 118 (61 %) 0.147
Hepatic 114 (14 %) 136 (11 %) 0.054 139 (32 %) 52 (27 %) 0.222
Coagulation 239 (29 %) 226 (19 %) <0.001 352 (81 %) 140 (73 %) 0.015
Primary source of infection <0.001 0.257
Abdomen 304 (37 %) 342 (28 %) - 156 (36 %) 79 (41 %) -
Lung 205 (25 %) 383 (31 %) - 64 (15 %) 25 (13 %) -
Urinary tract 113 (14 %) 199 (16 %) - 108 (25 %) 36 (19 %) -
Bone/soft tissue 102 (13 %) 145 (12 %) - 44 (10 %) 18 (9 %) -
Central nervous system 15 (2 %) 22 (2 %) - 15 (4 %) 5 (3 %) -
Other/unknown 75 (9 %) 132 (11 %) - 46 (11 %) 30 (16 %) -
Other therapeutic interventions
Immunoglobulin 377 (46 %) 179 (15 %) <0.001 213 (49 %) 31 (16 %) <0.001
Low-dose steroid 248 (31 %) 184 (15 %) <0.001 153 (35 %) 39 (20 %) <0.001
Renal replacement therapy 351 (43 %) 204 (17 %) <0.001 215 (50 %) 60 (31 %) <0.001
PMX-DHP 251 (31 %) 137 (11 %) <0.001 159 (37 %) 27 (14 %) <0.001
Surgical intervention 415 (51 %) 458 (37 %) <0.001 202 (47 %) 78 (40 %) 0.164
Data are expressed as group medians (interquartile range) or proportion (%). DIC disseminated intravascular coagulation, ISTH International Society on Thrombosis
and Haemostasis, SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health
Evaluation, JAAM Japanese Association for Acute Medicine, ICU intensive care unit, PMX-DHP polymyxin B direct haemoperfusion
Yamakawa et al. Critical Care  (2016) 20:229 Page 6 of 12
reduction in mortality associated with anticoagulant
therapy was observed in the moderate-risk and high-risk
subsets (APACHE II scores 20–30 and 36–43, respect-
ively), whereas in the low-risk subset (APACHE II score
≤19), there was no difference between the anticoagulant
and control groups. In terms of each organ dysfunction,
associations between anticoagulant therapy and better
outcome were observed only in the subset with organ
dysfunction such as respiratory, cardiovascular, renal,
and hepatic dysfunction, i.e. only in the population with
greater illness severity.
Adverse events
Bleeding complications stratified by baseline SOFA score
subsets are presented in Table 3. Rates of transfusion re-
quirement related to bleeding tended to increase in the
treated groups compared with those in the untreated
groups in any SOFA subset, but the differences were not
statistically significant. Other outcomes, such as occur-
rence of intracranial haemorrhage and bleeding requiring
surgical intervention, were similar in the treated and un-
treated groups of any SOFA subset.
Discussion
Summary of evidence
Numerous large clinical trials of anticoagulant agents
did not show a reduction in mortality among all patients
with sepsis [8, 9, 11]; thus, it is important to identify spe-
cific subsets of patients with sepsis who can benefit from
anticoagulant therapy. The present study represents the
first attempt to evaluate the benefit profile of anticoagu-
lant therapy in patients with sepsis. The current analyses
provide evidence that anticoagulant therapies were asso-
ciated with lower mortality in the DIC-positive subset,
but no such association was evident in the DIC-negative
subset. A similar benefit profile was observed in the ana-
lysis of the subsets stratified by SOFA score: a significant
association between anticoagulant therapy and reduction
in mortality was observed in a high-risk subset of patients
with sepsis (SOFA score 13–17) but not in the low-risk to
moderate-risk subsets (SOFA score ≤12). Furthermore, in
patients with sepsis the association between anticoagulant
therapy and better outcome was greater in patients
with organ dysfunction than in those without organ
dysfunction. Overall, the present analyses suggest that
Fig. 3 Adjusted estimated survival curves in patients with or without disseminated intravascular coagulation (DIC) diagnosed by ISTH overt DIC
criteria (a) and JAAM DIC criteria (b). The solid line represents patients in the anticoagulant group, and the dotted line represents patients in the
control group. ISTH International Society on Thrombosis and Haemostasis, JAAM Japanese Association for Acute Medicine
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anticoagulant therapies may only be effective in sepsis
among patients with DIC involving a high risk of
death. Thus, future RCTs of anticoagulant therapy for
sepsis should focus on specific populations, such as
those with sepsis-induced DIC, multiple organ dys-
function, or very severe disease.
Treatment effects according to baseline DIC status
Our study showing a significant association between
anticoagulant therapy and reduced mortality only in the
DIC-positive subset agreed with the findings of many
observational studies and post hoc subgroup analyses of
RCTs [15, 23, 24]. It also showed that anticoagulant
therapy is not associated with better outcome when it is
administered to patients without DIC. These observations
are explained by recent pathophysiological evidence on the
innate immune response. Under certain circumstances,
thrombosis is considered to play a major physiological role,
termed “immunothrombosis”, in immune defence [25–27].
In the non-DIC subset of patients, anticoagulant therapy
could have inhibited host-defensive thrombosis, which
helps to capture and ensnare pathogens circulating in the
blood, and therefore failed to improve mortality. However,
in patients with DIC, impairment of the anticoagulant sys-
tem leads to the overwhelming formation of fibrin and the
uncontrolled activation of immunothrombosis, which
play a critical role in inducing multiple organ dysfunc-
tion syndrome and subsequent death. Therefore, it is
reasonable to assume that anticoagulant therapy to inhibit
the over-activated coagulation cascade may be useful to
improve outcomes in this subset of patients.
Treatment effects according to baseline disease severity
Our findings on the association between anticoagulant
therapy and lower mortality according to disease severity
or organ dysfunction agrees with those of many previous
studies including a large multicentre RCT of activated
protein C or antithrombin [7, 14, 28]. Additionally, our
previous meta-analysis of the risk and efficacy of rhTM
in sepsis suggests that its efficacy would increase as the
risk of death increased [29].
Why were the effects of anticoagulant therapies in this
study more evident only when they targeted severely ill pa-
tients? One possible reason is that patients who are se-
verely ill are likely to present simultaneously with DIC,
which is related to immunothrombosis. Second, differences
between groups are likely to be statistically significant if
the control event rate is high. Third, anticoagulants such
as antithrombin and rhTM have specific anti-inflammatory
activities unrelated to anticoagulant activity [30–32], and
these anti-inflammatory effects might be clinically evident
only in the severely ill patients.
Adverse events
Bleeding was the most significant adverse event associated
with anticoagulant administration. Although the differences
Fig. 4 Adjusted estimated survival curves in 4 subsets stratified according to baseline Sequential Organ Failure Assessment (SOFA) score (a-d). The solid
line represents patients in the anticoagulant group, and the dotted line represents patients in the control group
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were not statistically significant, there was a consistent
tendency for bleeding-related transfusions to increase
in all of the severity subsets (13–27 % in the anticoagulant
group vs. 6–10 % in the control group). The decision
to use an anticoagulant depends on the balance between
efficacy and the safety of the intervention. Our results
showed that anticoagulant therapy may only be useful
in the sepsis subset with severe disease because of its
beneficial effects on mortality and the relatively low
risk of bleeding complications. In contrast, anticoagu-
lant therapy in the overall sepsis population including
the low-risk subset should not be recommended be-
cause of the risk of bleeding complications and lack
of survival benefit.
Limitations
We acknowledge several limitations of our study. First, it
is a non-randomised cohort study and hence suffers from
potential selection and ascertainment bias. The indications
for treatment and methodology for the treatment inter-
vention being examined were not standardised. The base-
line characteristics and intensity of ICU treatments other
than anticoagulant therapies were different between
the two groups. To cope with these imbalances caused by
non-randomisation, we developed a propensity score
approach that forces the analysts to explicitly focus
on these biases.
Second, the registry data used in the study were
retrospectively collected and did not capture detailed
Fig. 5 In-hospital mortality across subsets defined according to several baseline characteristics. HR hazard ratio, CI confidence interval, ISTH
International Society on Thrombosis and Hemostasis, DIC disseminated intravascular coagulation, JAAM Japanese Association for Acute Medicine,
SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation
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information that may be considered as confounding,
such as the timing or duration of anticoagulant ther-
apies. We are not confident that biased estimation of
the effects can be completely excluded despite robust
adjustment with propensity scores.
Third, the present multicentre study did not focus on
the treatment effects of specific anticoagulants. Thus,
the knowledge obtained from the present study might
be inadequate to influence decision making in clinical
settings. To verify our hypothesis, we assumed that
several of the anticoagulant agents displayed similar
effects against sepsis, even though these agents have
unique anticoagulant/antiinflammatory mechanisms and
pharmacological features. Also, low-dose anticoagulants
as prophylaxis against venous thromboembolism were
included in both groups. The combination of these three
major limitations might cause multiple unmeasured
confounders to account for the differences in outcome
observed in this study.
Finally, because this study involves subgroup analysis,
we cannot deny the potential of accidental false-positive
results. The study is also prone to false-negative results
due to inadequate power with which to uncover differences
in treatment effect, even in the presence of true treatment-
effect modification. Further multicentre prospective rando-
mised trials are therefore required to specifically evaluate
efficacy and safety.
Conclusions
Our post hoc subgroup analysis using the multicentre
nationwide J-Septic DIC registry in Japan demonstrated
an association between anticoagulant therapy and lower
mortality only in specific patients with sepsis, who are
severely ill and have multiple organ dysfunction, or DIC.
Thus, future RCTs of anticoagulant therapy for sepsis
should focus on such specific patient populations.
Key messages
 Patients who will highly benefit from anticoagulant
therapy against sepsis require identification
 Effects of anticoagulant therapy were evaluated by
baseline disseminated intravascular coagulation
status and by stratifying disease severity subsets
 Significant associations between anticoagulant
therapy and survival were shown only in specific
subsets of sepsis-induced disseminated intravascular
coagulation or very severe disease
 Future randomised controlled trials of anticoagulant
therapy for sepsis should focus on such specific
patient populations
Additional file
Additional file 1 Online supplemental data. (DOCX 63 kb)
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Table 3 Bleeding complications in subsets stratified according to baseline SOFA scores
Anticoagulant group Control group OR (95 % CI) P value
Transfusion related to bleeding
SOFA score ≤7 36/274 (13 %) 40/665 (6 %) 1.414 (0.817, 2.447) 0.216
SOFA score 8–12 84/615 (14 %) 42/554 (8 %) 1.306 (0.836, 2.041) 0.241
SOFA score 13–17 55/328 (17 %) 14/177 (8 %) 1.739 (0.886, 3.412) 0.108
SOFA score ≥18 8/30 (27 %) 2/20 (10 %) 9.516 (0.861, 105.193) 0.066
Intracranial haemorrhage
SOFA score ≤7 3/274 (1 %) 1/665 (0.2 %) 6.142 (0.501, 75.288) 0.156
SOFA score 8–12 3/615 (0.5 %) 2/554 (0.4 %) 0.608 (0.080, 4.600) 0.630
SOFA score 13–17 1/328 (0.3 %) 1/177 (0.6 %) 0.286 (0.016, 5.268) 0.400
SOFA score ≥18 0/20 (0 %) 0/30 (0 %) - -
Surgical interventions
SOFA score ≤7 3/274 (1 %) 1/665 (0.2 %) 7.634 (0.642, 90.792) 0.108
SOFA score 8–12 10/615 (2 %) 7/554 (1 %) 1.001 (0.326, 3.074) 0.998
SOFA score 13–17 7/328 (2 %) 3/177 (2 %) 0.824 (0.188, 3.608) 0.797
SOFA score ≥18 1/30 (3 %) 0/20 (0 %) - -
Data are expressed as number (percent) or OR (95%CI). SOFA Sequential Organ Failure Assessment, OR odds ratio, CI confidence interval
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